Vascular failure or sick vessel syndrome: The cardiovascular continuum is a useful concept for clinical research

Journal of Hypertension

Volumn 24, Issue 11, 2006, Pages 2147-2148

  Delles, Christian ^a   Dominiczak, Anna F ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; GLUTATHIONE DISULFIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MALONALDEHYDE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; METABOLIC DISORDER; OXIDATIVE STRESS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SICK VESSEL SYNDROME; SMOOTH MUSCLE; VASCULAR DISEASE; VASCULAR FAILURE;

EID: 33750242111     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000249687.43123.d2     Document Type: Editorial

References (25)

1. Inoue T, Node K. Vascular failure - a new entity for vascular disease. J Hypertens 2006; 24:2121-2130.
2. Dzau VJ. Markers of malign across the cardiovascular continuum: interpretation and application. Circulation 2004; 109 (25 Suppl 1): IV1-IV2.
3. Heistad DD, Armstrong ML. Sick vessel syndrome. Can atherosclerotic arteries recover? Circulation 1994; 89:2447-2450.
4. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104:2673-2678.
5. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, Schmieder RE. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998; 98:211-216.
6. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101:2349-2354.
7. Weber T, Auer J,O'Rourke MF, Kvas E, Lassnig E, Berent R, Eber B. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 2004; 109:184-189.
8. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113:664-670.
9. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 2003; 23:554-566.
10. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340:14-22.
11. Gaeta G, De Michele M, Cuomo S, Guarini P, Foglia MC, Bond MG, Trevisan M. Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med 2000; 343:840-846.
12. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, Kastelein JJ. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004; 109 (23 Suppl 1):III33-III38.
13. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
14. Amar J, Fauvel J, Drouet L, Ruidavets JB, Perret B, Chamontin B, et al. Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J Hypertens 2006; 24:1083-1088.
15. Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001; 358:971-976.
16. Redon J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Saez GT. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41:1096-1101.
17. Al-Benna S, Hamilton CA, McClure JD, Rogers PN, Berg GA, Ford I, et al. Low-density lipoprotein cholesterol determines oxidative stress and endothelial dysfunction in saphenous veins from patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2006; 26:218-223.
18. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003; 349:1605-1613.
19. Thongboonkerd V. Genomics, proteomics and integratibe 'omics' in hypertension research. Curr Opin Nephrol Hypertens 2005; 14:133-139.
20. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventive and personalized medicine. J Proteome Res 2004; 3:179-196.
21. International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437:1299-1320.
22. Couzin J. Genomics. The HapMap gold rush: researchers mine a rich deposit. Science 2006; 312:1131.
23. Kolch W, Mischak H, Pitt AR. The molecular make-up of a tumour: proteomics in cancer research. Clin Sci (Lond) 2005; 108:369-383.
24. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002; 8:1439-1444.
25. Watkins H, Farrall M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet 2006; 7:163-173.